NCT07148427View on ClinicalTrials.gov

Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

September 30, 2028

Conditions
Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy

Iparomlimab and Tuvonralimab：5mg/kg，Intravenous infusion，Q3W regorafenib：80mg，oral administration once daily from Day 1 to Day 14 chemotherapy：XELOX or SOX

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER